Coherus Capital Lease Obligations from 2010 to 2024
| CHRS Stock | USD 0.88 0.03 3.53% |
Capital Lease Obligations | First Reported 2019-03-31 | Previous Quarter 6.5 M | Current Value 5.6 M | Quarterly Volatility 2.2 M |
Check Coherus BioSciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Coherus BioSciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Interest Expense of 42.6 M or Selling General Administrative of 100.1 M, as well as many indicators such as Price To Sales Ratio of 1.16, Dividend Yield of 0.0 or Days Sales Outstanding of 388. Coherus financial statements analysis is a perfect complement when working with Coherus BioSciences Valuation or Volatility modules.
Coherus | Capital Lease Obligations |
Latest Coherus BioSciences' Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Coherus BioSciences over the last few years. Coherus BioSciences capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Coherus BioSciences asset purchases. For example, Coherus BioSciences can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Coherus BioSciences control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Coherus BioSciences' Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Coherus BioSciences' overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Coherus Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 9,848,896 | |
| Geometric Mean | 9,797,908 | |
| Coefficient Of Variation | 9.86 | |
| Mean Deviation | 675,233 | |
| Median | 10,256,000 | |
| Standard Deviation | 971,075 | |
| Sample Variance | 943B | |
| Range | 3.3M | |
| R-Value | (0.63) | |
| Mean Square Error | 610.3B | |
| R-Squared | 0.40 | |
| Significance | 0.01 | |
| Slope | (137,171) | |
| Total Sum of Squares | 13.2T |
Coherus Capital Lease Obligations History
About Coherus BioSciences Financial Statements
Coherus BioSciences shareholders use historical fundamental indicators, such as Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Coherus BioSciences investors may analyze each financial statement separately, they are all interrelated. The changes in Coherus BioSciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Coherus BioSciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 7.5 M | 7.6 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.